Zhang Kejie, Desai Aakash, Zeng Dongfeng, Gong Tiejun, Lu Peihua, Wang Michael
Department of Hematology, Zhongshan Hospital, Xiamen University, Fujian Medical University Clinic Teaching Hospital, Xiamen, China.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncotarget. 2017 Feb 7;8(6):10748-10759. doi: 10.18632/oncotarget.13314.
Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.
尽管有多种抗癌药物可供使用，但在大多数情况下，多发性骨髓瘤（MM）仍然无法治愈，并且使用这些药物治疗的患者复发率很高。2015年，我们在对抗多发性骨髓瘤的战斗中取得了重大进展。2015年，美国食品药品监督管理局（FDA）批准了三种用于多发性骨髓瘤的新疗法，即伊沙佐米（一种口服蛋白酶体抑制剂）、达雷妥尤单抗和埃罗妥珠单抗（分别针对CD38和信号淋巴细胞激活分子家族成员7的单克隆抗体）。本综述的目的是对上述突破性疗法以及在2015年美国血液学会（ASH）年会上展示的另外两种较新的药物菲拉尼西布（驱动蛋白纺锤体抑制剂）和塞利尼索（选择性核输出抑制剂）进行详细分析。我们还描述了靶向程序性死亡受体1（PD-1）轴的药物和嵌合抗原受体T（CAR-T）细胞在多发性骨髓瘤治疗中的作用。
